Merrimack Pharmaceuticals, Inc. (MACK)
-NasdaqGM 6.42 
0.03(0.47%) 3:59PM EDT
| Prev Close: | 6.39 |
|---|
| Open: | 6.37 |
|---|
| Bid: | 5.85 x 500 |
|---|
| Ask: | 6.50 x 200 |
|---|
| 1y Target Est: | 12.60 |
|---|
| Beta: | 1.677 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 6.11 - 6.50 |
|---|
| 52wk Range: | 4.06 - 11.11 |
|---|
| Volume: | 598,662 |
|---|
| Avg Vol (3m): | 358,345 |
|---|
| Market Cap: | 616.88M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.02 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Thu, Jun 13)
- Merrimack to Present at the Goldman Sachs 34th Annual Global Healthcare ConferenceGlobeNewswire(Thu, Jun 6)
- 4 Healthcare Stock Stories Attracting Attention Todayat Wall St. Cheat Sheet(Tue, Jun 4)
- Merrimack Pharmaceuticals' Phase 1 Research Supports MM-121 Potential for Investigation as Combination With Chemotherapy in Patients With Advanced Solid TumorsGlobeNewswire(Tue, Jun 4)
- 3 Innovative Biotech Companies With Promising Cancer Therapiesat Seeking Alpha(Wed, May 29)
- Merrimack completes enrollement in a Phase 2 study of MM-121 with Sanofiat theflyonthewall.com(Thu, May 23)
- Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Exemestane in Breast CancerGlobeNewswire(Thu, May 23)
- Thrifty Merrimack developing new cancer drugs at lower costat Reuters(Wed, May 22)
- MERRIMACK PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Fri, May 17)
- Merrimack's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 15)
- Merrimack Reports First Quarter 2013 Financial ResultsGlobeNewswire(Mon, May 13)
- Q1 2013 Merrimack Pharmaceuticals Inc Earnings Release - Time Not SuppliedCCBN(Mon, May 13)
- MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsEDGAR Online(Mon, May 13)
- Predicting Biotech Stock Moves Using Top Consensus Picks By Legendary Fund Managersat Seeking Alpha(Sun, May 5)
- Merrimack to Present at Multiple Investor Conferences This SpringGlobeNewswire(Thu, May 2)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 11.76 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.04 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.28 |
|---|
| Mean Recommendation*: | 1.3 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer in the United States.
View More